Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Merck Sharp & Dohme LLC
Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria G Atkinson; Stéphane Dalle; Andrew M Haydon; Andrey Meshcheryakov; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Anna Maria Di Giacomo; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul C Lorigan; Alexander C J van Akkooi; Clemens Krepler; Nageatte Ibrahim; Sandrine Marreaud; Michal Kicinski; Stefan Suciu; Caroline Robert